Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gene variant may explain why some People's 'Good' cholesterol works better

NCT ID NCT03109067

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how a common gene variation (TaqIB) affects the function of HDL, or 'good' cholesterol, after a meal. Researchers compared two groups of healthy men with different versions of this gene to see how well their HDL could remove cholesterol from cells. The goal was to better understand why some people are more protected from heart disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help explain why some people have better heart protection from HDL cholesterol, potentially guiding future personalized prevention strategies.
What could go wrong
This is a small, completed observational study in healthy men only. It does not test a treatment, so it cannot directly lead to a new therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Sep 2011

Finished

Nov 2015

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Affiliation to a national social security scheme 2. Age between 18 and 60 years old 3. Male subjects 4. Participants harboring either a B2 (genotype AA) allele or a B1 (genotype GG) in TaqIB polymorphism of CETP gene 5. Fasted plasmatic triglyceridemia \< 300 mg/dL 6. Free prior and informed written consent given by the participant Exclusion Criteria: 1. Participants with an history of symptomatic cardio-vascular disease (infarct, angina pectoris, acute coronary syndrome, cardiac surgery, endoluminal coronal intervention, stroke, symptomatic peripheral artery disease) within 6 months prior to inclusion. 2. Triglyceridemia \> 3 g/L 3. Participants having other lipid-lowering agents than statin (fibrate, niacin, ezetimibe) 4. Participants having a treatment (either systemic or local) which might interfere with the evaluation of study parameters. 5. Excessive alcohol consumption, or any drug addiction. An excessive alcohol consumption is superior to 21 time 30 mL of alcohol or 120 mL of wine or 355 mL of beer. 6. Regular smoker or smoking cessation within the last year 7. Significant abnormality on the full blood count or plasmatic and urinary biochemistry analysis. 8. Chronic or acute disease either life threatening or able to modify study results, including among others : 1. Diabetes 2. Renal diseases : nephrotic syndrome, chronic kidney failure and/or creatininemia \> 1.7 time the upper limit of normal (ULN). 3. Hypothyroidism defined by thyroid-stimulating hormone \> 2x ULN 4. Hepatobiliary disease or viral hepatitis B or C confirmed by transaminases \> 2x ULN or alkaline phosphatase \> 1.5x ULN or total bilirubinemia \> 1.5x ULN at screening. 5. Known HIV 6. Gastro-intestinal disorder or disease that might modify intestinal absorption, bariatric surgery. 9. Participant who might interfere with the quality of the study or might compromise the study according to the investigator. 10. Participant currently enrolled in another study or in the exclusion period of another study. 11. Participants with uncontrolled hypertension defined by a systolic blood pressure \> 140 mmHg or a diastolic blood pressure \> 90 mmHg. 12. Participants with a C reactive protein (CRP) \> 5mg/L 13. Participants with a E2/E2 phenotype of apolipoprotein E. 14. Blood donation or product derived-from blood donation within the last 3 months prior to the test meal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre d'Investigation Clinique Paris Est

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.